Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First Single-Dose Cholera Vaccine Approved By FDA



The vaccine is designed to protect against cholera infection and is the world’s first single-dose preventative treatment.

Share this!

June 15, 2016 | by Sarah Massey, M.Sc.

Tweet: World's first #cholera #vaccine approved by #FDA http://ctt.ec/kUGBl+

An oral cholera vaccine, PaxVax’s Vaxchora, has just been approved by the US Food and Drug Administration (FDA). The vaccine is designed to protect against cholera infection and is the world’s first single-dose preventative treatment.

“The approval of Vaxchora represents a significant addition to the cholera-prevention measures currently recommended by the Centers for Disease Control and Prevention for travelers to cholera-affected regions,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. The vaccine is a live, attenuated bacteria which is administered via a single oral dose at least 10 days before an individual plans to travel to a cholera-endemic area.

Between 1.4 million and 4.3 million people worldwide become infected with cholera each year, according to statistics from the World Health Organization (WHO). The bacterial infection causes severe diarrhea which can be fatal just hours after the onset of symptoms.

While the Centers for Disease Control and Prevention (CDC) recommend that US travelers prevent infection with Vibrio cholera bacteria by avoiding suspicious food and water, most travelers fail to comply with these guidelines. It’s estimated that 98 percent of travelers to cholera-endemic regions – including those in the Caribbean, Asia and Africa – don’t heed the CDC’s warning.

Most travelers who develop cholera while visiting one of the 69 countries where the illness is common, do not die. They do, however, suffer from severely acute symptoms including dehydration and diarrhea. Without proper medical attention, a patient with cholera could die in less than 48 hours.

Interestingly, the CDC claims that the number of cholera cases in the US is severely underestimated. They believe that the actual number of patients who become ill as a result of the Vibrio cholera bacteria could be as much as 30 times higher than the estimate made using epidemiological methods.

Vaxchora was granted both fast track designation and priority review status by the FDA. PaxVax now hopes to make the vaccine available to those living in cholera-endemic countries.

Keywords: Cholera, Vaccine, FDA


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.